소프트젤 캡슐 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the softgel capsules market size is expected to grow from USD 8.86 billion in 2025 to USD 9.38 billion in 2026 and is forecast to reach USD 12.49 billion by 2031 at 5.9% CAGR over 2026-2031.

This report is Segmented by Shell Source (Gelatin (Animal-Based) and Non-Animal-Based), Application (Pharmaceuticals, Nutraceuticals and Dietary Supplements, Cosmetics and Personal Care, and Other Applications) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Softgel Capsules Market Trends and Insights

Technological Advancements and Rising R&D Spend

Pharmaceutical developers are reallocating budgets toward delivery formats that boost bioavailability, with softgels emerging as a preferred option for poorly soluble APIs. Evonik's EUDRAGIT FL 30 D-55 cuts preparation times by 70%, thus compressing scale-up windows and reducing capital lock-in. Patent filings for thioureylene liquids targeting hyperthyroidism and Bacopa monnieri complexes underscore the platform's versatility. Integrated CDMOs now bundle formulation, analytical, and commercial production under one roof, trimming tech-transfer friction and speeding launches, a trend highlighted by Novo Holdings' Catalent takeover.

Growing Demand from Health-Conscious Consumers

Shifts toward plant-centric, transparent labeling continue to amplify HPMC and pullulan adoption. Nearly half of supplement users now prefer capsules, citing easier swallowing, odor masking, and quicker onset. Manufacturers are responding by investing in vegan-certified production lines and developing innovative shell materials like carrageenan and pectin-based systems that maintain functionality while meeting dietary restrictions. The convergence of health consciousness and ethical consumption patterns is reshaping product development priorities across the industry.

Product Leakage and Heat-Humidity Stability Issues

Moisture uptake can weaken seams and hasten oxidation, a critical concern for temperature-sensitive omega-3 fills in tropical regions. Traditional gelatin shells exhibit moisture absorption rates that can compromise seal integrity under extreme conditions, leading to product leakage and reduced shelf-life stability. Advanced Healthcare Materials research published in 2024 emphasized the critical importance of shell formulation optimization using differential scanning calorimetry and mechanical testing to ensure product quality throughout storage conditions. Advances in moisture-barrier coatings and plasticizer blends demonstrate lab-scale promise but await regulatory clearance for broad commercial use.

Other drivers and restraints analyzed in the detailed report include:

1. Aging Population Seeking Easy-to-Swallow Formats
2. Precision Enteric Softgels for Biologics Pipeline
3. Stringent Sourcing / BSE-Free Gelatin Regulations

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The gelatin category controlled 81.72% of softgel capsules market share in 2025, supported by reliable supply chains and proven mechanical strength. Nevertheless, non-animal shells are expanding at a 6.9% CAGR as regulatory scrutiny over BSE and consumer ethics motivates formulators to switch. HPMC shells provide moisture protection and faster disintegration, while pullulan offers superior oxygen barriers that safeguard antioxidants and probiotics. Carrageenan and pectin systems are advancing but still face commercial-scale hurdles. Competitive differentiation hinges on balancing shell clarity, seal integrity, and line throughput.

Expanded capacity for plant-based capsules is reshaping supply dynamics. IFF Pharma Solutions markets non-GMO HPMC options designed for hygroscopic botanicals. Gelatin suppliers respond with specialty grades such as low-endotoxin bovine and porcine derivatives compliant with strict pharmacopeial limits. Innovation remains two-pronged: upgrade traditional gelatin while commercializing next-generation vegan alternatives. The softgel capsules market continues to reward players that can flex production lines between both materials without downtime.

Complete Report Scope:

• By Shell Source
  • Gelatin (Animal-based)
  • Non-animal-based
• By Application
  • Pharmaceuticals
  • Nutraceuticals and Dietary Supplements
  • Cosmetics and Personal Care
  • Other Applications
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America maintained leadership with 33.22% of 2025 revenue, powered by deep R&D pipelines, extensive CDMO capacity, and clear FDA pathways that shorten time-to-market. The region benefits from an aging demographic that values swallowable formats and a mature e-commerce nutraceutical channel that promotes personalized packs. Canada's tax incentives for pharmaceutical R&D and Mexico's cost-competitive fill-finish sites complement U.S. capacity, fostering a regional cluster effect.

Europe ranks second, characterized by high quality standards and strict gelatin provenance checks following the 2024 EFSA risk reassessment. Germany's Aenova Group runs multi-site gelatin and vegan softgel lines, while Italy, France, and Spain house specialized CDMOs supporting regional brand owners. Eastern European facilities in Croatia and Poland attract investment as lower-cost hubs that still meet EU GMP.

Asia-Pacific is the fastest riser at 7.7% CAGR, fueled by new plants in Thailand, South Korea, and India that diversify supply chains beyond China. Sirio Pharma's USD 40 million Thai site and SK pharmteco's USD 260 million Korean expansion exemplify the regional capacity race. Japan's stringent quality culture and Australia's regulatory efficiency serve as gateways for APAC exports destined for Western markets. Rising healthcare expenditure, urbanization, and digital pharmacy adoption underpin sustained demand.

1. Catalent
2. Lonza (Capsugel)
3. Procaps Group (Softigel)
4. Aenova Group
5. Sirio Pharma
6. EuroCaps Ltd
7. CAPTEK Softgel International
8. Fuji Capsule
9. MEDGEL Co., Ltd.
10. Soft Gel Technologies
11. Robinson Pharma
12. Best Formulations
13. Strides Pharma Science Ltd.
14. Patheon (Thermo Fisher Scientific)
15. Suheung Capsule Co.
16. CapsCanada Corp.
17. Rousselot (Bioactive Health)
18. GELITA AG

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Technological Advancements and Rising R&D Spend
  • 4.2.2 Growing Demand from Health-Conscious Consumers
  • 4.2.3 Aging Population Seeking Easy-To-Swallow Formats
  • 4.2.4 Precision Enteric Softgels for Biologics Pipeline
  • 4.2.5 Subscription-Based Personalised Nutrition Models
  • 4.2.6 APAC CDMO Capacity Race (Supply-Chain Security)
• 4.3 Market Restraints
  • 4.3.1 Product Leakage and Heat-Humidity Stability Issues
  • 4.3.2 Stringent Sourcing / BSE-Free Gelatin Regulations
  • 4.3.3 Omega-3 Supply Volatility Inflating Fill Costs
  • 4.3.4 Scale-Up Barriers for Plant-Based Shell Sealing
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Intensity of Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Shell Source
  • 5.1.1 Gelatin (Animal-based)
  • 5.1.2 Non-animal-based
• 5.2 By Application
  • 5.2.1 Pharmaceuticals
  • 5.2.2 Nutraceuticals and Dietary Supplements
  • 5.2.3 Cosmetics and Personal Care
  • 5.2.4 Other Applications
• 5.3 By Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Catalent Inc.
  • 6.3.2 Lonza (Capsugel)
  • 6.3.3 Procaps Group (Softigel)
  • 6.3.4 Aenova Group
  • 6.3.5 Sirio Pharma
  • 6.3.6 EuroCaps Ltd
  • 6.3.7 CAPTEK Softgel International
  • 6.3.8 Fuji Capsule Co., Ltd.
  • 6.3.9 MEDGEL Co., Ltd.
  • 6.3.10 Soft Gel Technologies, Inc.
  • 6.3.11 Robinson Pharma
  • 6.3.12 Best Formulations
  • 6.3.13 Strides Pharma Science Ltd.
  • 6.3.14 Patheon (Thermo Fisher Scientific)
  • 6.3.15 Suheung Capsule Co.
  • 6.3.16 CapsCanada Corp.
  • 6.3.17 Rousselot (Bioactive Health)
  • 6.3.18 GELITA AG

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment